News About: Pharm. Affairs


Basic dispensing fee stays same at KRW 1,360 in 2018, KRW 5,460 for 3-day prescription

The 2018 medical fee negotiation for pharmacy drew a result of a 2.9% increase; the equivalent index, a unit cost per relative value point, was KRW 82.4. Based on a calculation of 2018’s pharmacy dispensing fees by a...

Approval trend of OTC medicines turns to ‘increase’ this year

Acquiring an increasing number of OTC products this year, pharmaceutical companies were analyzed to secure growth engines by energizing their OTC products. According to the Ministry of Food and Drug Safety, there wer...

KMA benefits from highest rate of increase at 2018 health insurance benefit negotiation

The 2018 health insurance benefit negotiation continued to be a war of nerves even at the end, but ‘all the categories’ were finally completed like the last year. The Korean Medical Association(KMA) dramatically conc...

Amplified concerns for delivery problem and return crisis after enforcement of serial number system

While there is only a month left for enforcement of the real-time serial number reporting system, there have been worries about delivery problems and crisis of return to medical institutes, such as pharmacies. When i...

Antihypertensive ‘Edarbi’ acquires approval from MFDS

Takeda Pharmaceuticals Korea(CEO Mahender Nayak, hereinafter referring to Takeda) announced ‘Edarbi(potassium azilsartan medoxomil),’ an essential hypertensive treatment, acquired commercialization approval from the M...

Would it be illegal to inject a drug to pets, but purchasing it at animal pharmacy is okay?

When it comes to the Ministry of Agriculture, Food and Rural Affairs’(MAFRA) action of allowing everyone to exercise subcutaneous injections, a series of veterinarians have started to make written opinions to stand ag...

1 of 3 incrementally modified drugs were antihypertensive

Since the adoption of the Incrementally Modified Drug Approval System in 2009, the total 82 pharmaceutical products were approved as incrementally modified drug, 1 of 3 modified drugs were antihypertensive. According...

Will ‘Vemlidy’ become a new power in chronic hepatitis B treatment market?

Pharmaceutical companies have been highly competitive to develop new chronic hepatitis B treatments. In the competition, Gilead developed a new drug called ‘Vemlidy(generic name: tenofovir alafenamide, aka. TAF)’ and ...

9 of 24 new drugs approved last year was antibiotic neoplastic agent

It was observed there were 24 pharmaceutical products approved as new drug in Korea, and 9 of them were anticancer drugs. In the recently-published ‘2016 Drug Approval Report,’ the Ministry of Food and Drug Safety an...

“Health insurance benefits for pharmacy must reflect the reality of the industry”

The Korean Pharmaceutical Association’s National Health Insurance Benefit Negotiation Team(Team Leader In-Choon Park, Mo-Sae Park, Yang-Yeon Cho, Yong-Hwa Lee) informed difficulties in managing pharmacies to the Natio...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.